Visual Abstract

Cannabis use is known to increase DKA risk in adults with T1D. We evaluated diabetes self-management, glycemic control, and its relationship with DKA risk in T1D by cannabis use. Adults with T1D followed at the Barbara Davis Center were invited for a survey between September and October of 2020. Information on demographics, cannabis use (CUDIT-R), self-reported DKA in the past year, self-reported A1c, and diabetes self-management (DSMQ) were collected using validated questionnaires. Of 905 respondents, 238 reported using cannabis (26.2%). Cannabis users were younger (mean±SD 31±12 vs. 37 ±15 y, p<0.0001), often men (42% vs. 33%, p=0.025), had shorter T1D duration (17±11 vs. 21±14 y, p<0.0001), higher A1c (7.8±1.7% vs. 7.4±1.5%, p=0.0006), lower use of pump (55% vs. 71%, p<0.0001) and continuous glucose monitoring (75% vs. 84%, p= 0.002), frequently missing meal-time (65% vs. 53%, p= 0.0015) or long-acting insulin (22% vs. 12%, p= 0.0011), and lower DSMQ scores (19±5 vs. 21±4, p<0.001) compared to non-users. Cannabis use was associated with a 1.8-fold increased DKA risk (10.08% vs. 6.02%, p=.0363), and the association attenuated when adjusted for HbA1c, pump use, DSMQ score and missing insulin doses (Figure). In adults with T1D, cannabis users had 2 fold increase in DKA risk, probably attributable to missing insulin doses and poor diabetes self-management leading to high A1c compared non-users.


D. Giese: None. G. L. Kinney: None. C. Geno rasmussen: None. J. K. Snell-bergeon: Stock/Shareholder; Self; GlaxoSmithKline plc. V. Shah: Advisory Panel; Self; Medscape, Sanofi, Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Sanofi, vTv Therapeutics.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at